Neurogene (NASDAQ:NGNE) CFO Sells $21,612.00 in Stock

Neurogene Inc. (NASDAQ:NGNE) CFO Christine Mikail Cvijic sold 600 shares of the stock in a transaction on Monday, July 6th. The stock was sold at an average price of $36.02, for a total value of $21,612.00. Following the transaction, the chief financial officer owned 88,240 shares of the company’s stock, valued at approximately $3,178,404.80. This represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Mikail Cvijic also recently made the following trade(s):

• On Tuesday, July 7th, Christine Mikail Cvijic sold 4,200 shares of Neurogene stock. The shares were sold at an average price of $36.13, for a total transaction of $151,746.00.
• On Thursday, July 2nd, Christine Mikail Cvijic sold 4,061 shares of Neurogene stock. The stock was sold at an average price of $34.82, for a total transaction of $141,404.02.
• On Wednesday, July 1st, Christine Mikail Cvijic sold 739 shares of Neurogene stock. The stock was sold at an average price of $34.06, for a total transaction of $25,170.34.
• On Wednesday, May 6th, Christine Mikail Cvijic sold 9,600 shares of Neurogene stock. The stock was sold at an average price of $31.25, for a total transaction of $300,000.00.

Neurogene Price Performance

Shares of NASDAQ NGNE traded up $4.24 during mid-day trading on Tuesday, hitting $36.80. The company had a trading volume of 708,181 shares, compared to its average volume of 246,656. The company has a market capitalization of $581.44 million, a PE ratio of -8.09 and a beta of 1.68. The business’s 50-day simple moving average is $29.70 and its 200 day simple moving average is $23.57. Neurogene Inc. has a 1-year low of $15.93 and a 1-year high of $37.27.

Neurogene (NASDAQ:NGNE) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.30) by ($0.09). On average, analysts expect that Neurogene Inc. will post -5.63 EPS for the current year.

Institutional Investors Weigh In On Neurogene

Several hedge funds have recently modified their holdings of the stock. Jennison Associates LLC grew its holdings in Neurogene by 35.3% in the fourth quarter. Jennison Associates LLC now owns 533,088 shares of the company’s stock valued at $10,982,000 after purchasing an additional 138,999 shares during the last quarter. ArrowMark Colorado Holdings LLC raised its stake in shares of Neurogene by 1.8% during the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 595,839 shares of the company’s stock worth $10,326,000 after buying an additional 10,442 shares during the last quarter. Blair William & Co. IL boosted its position in shares of Neurogene by 6.4% in the 3rd quarter. Blair William & Co. IL now owns 141,820 shares of the company’s stock worth $2,458,000 after buying an additional 8,584 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in Neurogene in the 4th quarter valued at about $669,000. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in Neurogene in the 4th quarter valued at about $575,000. 52.37% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on NGNE shares. Guggenheim assumed coverage on Neurogene in a report on Tuesday, April 28th. They issued a “buy” rating and a $69.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neurogene in a research report on Tuesday, April 21st. Rodman & Renshaw began coverage on Neurogene in a report on Wednesday, June 3rd. They issued a “buy” rating and a $70.00 price objective on the stock. Canaccord Genuity Group cut their target price on Neurogene to $180.00 and set a “buy” rating on the stock in a research report on Monday, April 6th. Finally, UBS Group set a $70.00 price target on Neurogene in a report on Wednesday, June 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Neurogene currently has an average rating of “Buy” and a consensus price target of $84.83.

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.